로딩 중…
StockDiggingStockDigging

DAEWON PHARMACEUTICAL CO.,LTD

003220· KOSPI
₩8,540-2.95%
2026-06-19

Price Chart

DAEWON PHARMACEUTICAL CO.,LTD-36.36%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap191.53B KRW
Revenue605.66B KRW
Net Income10.09B KRW
Total Assets595.99B KRW
Net Assets270.98B KRW
Employees1,332
Value
P/E18.97x
P/B0.71x
P/S0.32x
EV/EBITDA633.63x
FCF Yield6.53%
Profitability
ROE3.73%
ROA1.69%
Op. Margin0.14%
Revenue Growth0.14%
Earnings Growth-64.60%
Financial Health
Debt Ratio219.94%
Total Debt361.11B KRW
FCF12.51B KRW
Cash27.95B KRW
Current Ratio1.18x
Dividend
Div. Yield2.84%
Div. Growth-16.67%
Performance
1Y Return-36.36%
1M Return-8.27%
From 52W High-39.39%
1Y MDD-41.37%
Trading
Volume132,565 shares
Foreign Own.12.99%
Per Share
EPS-195 KRW
BPS12,263 KRW

Company Info

CEO 백승열, BAEK JONATHAN IN
Employees 1,332
Founded 1961
HQ 서울특별시 성동구, KR

Daewon Pharmaceutical, incorporated in 1961, currently holds 11 subsidiaries, with Beijing Skinlala's liquidation expected by 2025. The company's core business involves manufacturing and selling pharmaceuticals, cosmetics, and health functional foods, supplying new drugs, incrementally modified drugs, and generic drugs to domestic medical institutions. Leveraging excellent GMP-certified production facilities and specialized products, Daewon Pharmaceutical engages in CMO business, exports finished pharmaceuticals and medical devices, and operates a health functional food business focused on Jangdaewon. The company is headquartered in Seongdong-gu, Seoul.